| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Cho, R D Hayes, A Jewell, G Kadra, H Shetty, J H MacCabe, J Down. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta psychiatrica Scandinavica. vol 139. issue 3. 2020-04-16. PMID:30478891. |
clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. |
2020-04-16 |
2023-08-13 |
Not clear |
| J Cho, R D Hayes, A Jewell, G Kadra, H Shetty, J H MacCabe, J Down. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta psychiatrica Scandinavica. vol 139. issue 3. 2020-04-16. PMID:30478891. |
large-scale epidemiological studies have demonstrated a protective effect of clozapine on mortality in people with schizophrenia. |
2020-04-16 |
2023-08-13 |
Not clear |
| J Cho, R D Hayes, A Jewell, G Kadra, H Shetty, J H MacCabe, J Down. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta psychiatrica Scandinavica. vol 139. issue 3. 2020-04-16. PMID:30478891. |
clozapine is reserved for use in patients with treatment-resistant schizophrenia (trs), but evidence of clozapine's effect on mortality exclusively within trs samples is inconclusive. |
2020-04-16 |
2023-08-13 |
Not clear |
| Dilhan Esen-Sehir, Michael J Courtney, Robert A Bittner, Andreas Reif, Florian Freudenber. Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice. Acta neuropsychiatrica. vol 31. issue 6. 2020-04-13. PMID:31364522. |
despite its numerous side effects, clozapine is still the most effective antipsychotics making it an ideal reference substance to validate the efficacy of novel compounds for the treatment of schizophrenia. |
2020-04-13 |
2023-08-13 |
mouse |
| Susana Alberich, Jessica Fernández-Sevillano, Itxaso González-Ortega, Judith Usall, Marga Sáenz, Eduardo González-Fraile, Ana González-Pint. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. Psychiatry research. vol 280. 2020-04-07. PMID:31401291. |
clozapine is one of the most widely used antipsychotics for treating psychiatric illnesses such as schizophrenia and bipolar disorder. |
2020-04-07 |
2023-08-13 |
Not clear |
| Jentien M Vermeulen, Geeske van Rooijen, Marita P J van de Kerkhof, Arjen L Sutterland, Christoph U Correll, Lieuwe de Haa. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. Schizophrenia bulletin. vol 45. issue 2. 2020-04-06. PMID:29697804. |
clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. |
2020-04-06 |
2023-08-13 |
Not clear |
| Ching-Wen Chu, Chih-Sung Lian. Clozapine Might Relieve Rhinotillexomania and Related Epistaxis in Schizophrenia Patients: A Case Report. American journal of therapeutics. vol 26. issue 6. 2020-04-06. PMID:30741917. |
clozapine might relieve rhinotillexomania and related epistaxis in schizophrenia patients: a case report. |
2020-04-06 |
2023-08-13 |
Not clear |
| Jonathan G Leung, Joseph Cusimano, Jessica M Gannon, Olga Milgrom, Stephanie C Valcourt, Joseph B Stoklosa, Michael Kemp, William Olsufka, P Brittany Vickery, Stephanie D Nichols, Ericka L Crouse, Chris Paxos, Emily K Johnson, Brian A Palme. Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey. International clinical psychopharmacology. vol 34. issue 5. 2020-04-02. PMID:31107831. |
clozapine use has declined, despite its superior antipsychotic efficacy in treatment-resistant schizophrenia. |
2020-04-02 |
2023-08-13 |
Not clear |
| Theodore R Zarzar, Terri L Catlett, Maria G O'Connell, Bryan H Harrelson, Vincent P Wilson, Genell N Rashad, Dustin B Morris, Joseph B Williams, Susan S Peebles, Brian B Sheitma. Clozapine Reduces Self-Injurious Behavior in a State Prison Population. The journal of the American Academy of Psychiatry and the Law. vol 47. issue 1. 2020-03-26. PMID:30782606. |
the median dose of clozapine used was 125 mg/day, substantially lower than doses typically used to treat schizophrenia. |
2020-03-26 |
2023-08-13 |
Not clear |
| Harsh Pathak, Dinakaran Damodharan, Pavithra Jayasankar, Vanteemar S Sreeraj, Ganesan Venkatasubramania. Safety of clozapine in patient with treatment resistant schizophrenia & asymptomatic constitutional macrothrombocytopenia (Harris syndrome). Asian journal of psychiatry. vol 45. 2020-03-19. PMID:31569026. |
safety of clozapine in patient with treatment resistant schizophrenia & asymptomatic constitutional macrothrombocytopenia (harris syndrome). |
2020-03-19 |
2023-08-13 |
Not clear |
| Sophie E Legge, James Tr Walter. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics. vol 20. issue 4. 2020-03-18. PMID:30767710. |
clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. |
2020-03-18 |
2023-08-13 |
Not clear |
| Ragy R Girgis, Anthony W Zoghbi, Daniel C Javitt, Jeffrey A Lieberma. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of psychiatric research. vol 108. 2020-03-17. PMID:30055853. |
drug development for schizophrenia since that time has led to improvements in side effects and tolerability, and limited improvements in efficacy, with the exception of clozapine. |
2020-03-17 |
2023-08-13 |
Not clear |
| b' Francesco Bartoli, Cristina Crocamo, Carmen Di Brita, Giovanni Esposito, Tommaso Innocenzo Tabacchi, Enrica Verrengia, Massimo Clerici, Giuseppe Carr\\xc3\\xa. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis. Journal of psychiatric research. vol 108. 2020-03-17. PMID:30447508.' |
adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis. |
2020-03-17 |
2023-08-13 |
human |
| b' Francesco Bartoli, Cristina Crocamo, Carmen Di Brita, Giovanni Esposito, Tommaso Innocenzo Tabacchi, Enrica Verrengia, Massimo Clerici, Giuseppe Carr\\xc3\\xa. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis. Journal of psychiatric research. vol 108. 2020-03-17. PMID:30447508.' |
a fair amount of subjects with schizophrenia do not respond to clozapine and are defined 'ultra-resistant'. |
2020-03-17 |
2023-08-13 |
human |
| Stephen R Estime, Sheri M Berg, Michael E Henr. Clozapine-Associated Aspiration During Electroconvulsive Therapy. The journal of ECT. vol 35. issue 2. 2020-03-16. PMID:30308569. |
in this report, we present a patient with treatment refractory schizophrenia receiving high-dose clozapine who aspirated during general anesthesia for electroconvulsive therapy. |
2020-03-16 |
2023-08-13 |
Not clear |
| Mujeeb U Shad, Emma Felzien, Kamalika Roy, Simrat Seth. How to identify and manage non-response to clozapine? Asian journal of psychiatry. vol 45. 2020-03-13. PMID:31494348. |
clozapine is the only approved treatment for treatment-refractory schizophrenia. |
2020-03-13 |
2023-08-13 |
Not clear |
| Marta Szlachta, Maciej Kuśmider, Joanna Solich, Magdalena Kolasa, Paulina Pabian, Marta Dziedzicka-Wasylewska, Agata Faron-Góreck. Clozapine administered repeatedly following pretreatment with ketamine enhances dopamine D Neuroscience letters. vol 707. 2020-03-11. PMID:31132389. |
clozapine administered repeatedly following pretreatment with ketamine enhances dopamine d the mechanisms underlying the beneficial effects of clozapine (clz) in the treatment of schizophrenia still remains far from clear. |
2020-03-11 |
2023-08-13 |
Not clear |
| Zongping Xiong, Ming Cheng, Peng Zhu, Shiqiong Huang, Jun Guo, Wei Zhang, Honghao Zhou, Yan Shu, Qing L. Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients. Human psychopharmacology. vol 34. issue 4. 2020-03-11. PMID:31273857. |
the aim of this study was to investigate correlation of peripheral blood cell counts with the dyslipidemia induced by olanzapine or clozapine in chinese schizophrenia patients. |
2020-03-11 |
2023-08-13 |
Not clear |
| Davide Martino, Vikram Karnik, Sydney Osland, Thomas R E Barnes, Tamara M Pringshei. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2020-02-25. PMID:29758999. |
we conducted meta-analyses of randomised controlled trials included in the cochrane database of systematic reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with sgas (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, l-sulpiride, and ziprasidone) approved in canada and the uk, comparing them with haloperidol and chlorpromazine. |
2020-02-25 |
2023-08-13 |
Not clear |
| Mark Ponsford, Daniel Castle, Tayyeb Tahir, Rebecca Robinson, Wendy Wade, Rachael Steven, Kathryn Bramhall, Mo Moody, Emily Carne, Catherine Ford, Daniel Farewell, Paul Williams, Tariq El-Shanawany, Stephen Jolle. Clozapine is associated with secondary antibody deficiency. The British journal of psychiatry : the journal of mental science. 2020-02-25. PMID:30259827. |
clozapine is the only medication licensed for treatment-resistant schizophrenia and is intensively monitored to prevent harm from neutropenia. |
2020-02-25 |
2023-08-13 |
Not clear |